HIGHLIGHTS
- who: Alessandra Guido from the (UNIVERSITY) have published the paper: Adaptive Individualized high-dose preoperAtive (AIDA) chemoradiation in high-risk rectal cancer: a phase II trial, in the Journal: (JOURNAL)
- what: The aim was to assess the pCR rate after 18 F-FDGPET/CT-based neoadjuvant CRT. Unlike in the study , 18 F-FDG-PET/CT was carried out only before and not during CRT. The results of the trial showed that adaptive individualized high-dose neoadjuvant CRT delivered with simultaneous and sequential boosts planned with 18 F-FDGPET/CT is feasible and effective. In . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.